TRINTELLIX® (vortioxetine) is indicated for the treatment of Major Depressive Disorder (MDD) in adults.

Patient portrayal. 
Individual results may vary.

FAQs

Selective serotonin reuptake inhibitors (SSRIs) are a common type of antidepressant used to treat Major Depressive Disorder (MDD) by enhancing specific serotonergic activity in the CNS.14

The mechanism of the antidepressant effect of TRINTELLIX is not fully understood, although it is thought to be related to its enhancement of serotonergic activity through inhibition of the reuptake of serotonin (5-HT).1 It also has several other activities including 5-HT3 receptor antagonism and 5-HT1A receptor agonism. The contribution of these activities to TRINTELLIX's antidepressant effect has not been established.

For descriptions of MDD and a hypothetical patient profile, please see Patient Profile. 

The mean terminal half-life of TRINTELLIX is approximately 66 hours, and steady-state plasma concentrations are typically achieved within two weeks of dosing.1

Multiple drugs have the potential to interact with TRINTELLIX, including prescription and over-the-counter medicines, vitamins, and herbal supplements. TRINTELLIX and some drugs should not be taken concomitantly as co-administration may lead to serious side effects or decreases in efficacy.1

See below for clinically important interactions with TRINTELLIX.1

NOTE: this is not an exhaustive list of TRINTELLIX drug interactions. Please see the Full Prescribing Information for further information.

Monoamine Oxidase Inhibitors (MAOIs)

Clinical Impact

The concomitant use of SSRIs and SNRIs including TRINTELLIX with MAOIs increases the risk of serotonin syndrome.

Intervention

Concomitant use of TRINTELLIX is contraindicated:

  • With an MAOI intended to treat psychiatric disorders or within 21 days of stopping treatment with TRINTELLIX.
  • Within 14 days of stopping an MAOI intended to treat psychiatric disorders.
  • In a patient who is being treated with linezolid or intravenous methylene blue.
Examples

selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue

Other Serotonergic Drugs

Clinical Impact

Concomitant use of TRINTELLIX with other serotonergic drugs increases the risk of serotonin syndrome.

Intervention

Monitor for symptoms of serotonin syndrome when TRINTELLIX is used concomitantly with other drugs that may affect the serotonergic neurotransmitter systems. If serotonin syndrome occurs, consider discontinuation of TRINTELLIX and/or concomitant serotonergic drugs.

Examples

Other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. John's Wort

Strong Inhibitors of CYP2D6

Clinical Impact

Concomitant use of TRINTELLIX with strong CYP2D6 inhibitors increases plasma concentrations of vortioxetine.

Intervention

Reduce TRINTELLIX dose by half when a strong CYP2D6 inhibitor is coadministered.

Examples

bupropion, fluoxetine, paroxetine, quinidine

Strong CYP Inducers

Clinical Impact

Concomitant use of TRINTELLIX with strong CYP inducer decreases plasma concentrations of vortioxetine.

Intervention

Consider increasing the TRINTELLIX dose when a strong CYP inducer is coadministered. The maximum dose is not recommended to exceed three times the original dose.

Examples

rifampin, carbamazepine, phenytoin

Drugs that interfere with Hemostasis (antiplatlet agents and anticoagulants)

Clinical Impact

Concomitant use of TRINTELLIX with an antiplatelet or anticoagulant drug may potentiate the risk of bleeding.

Intervention

Inform patients of the increased risk of bleeding associated with the concomitant use of TRINTELLIX and antiplatelet agents and anticoagulants. For patients taking warfarin, carefully monitor the international normalized ratio.

Examples

aspirin, clopidogrel, heparin, warfarin

Drugs Highly Bound to Plasma Protein

Clinical Impact

TRINTELLIX is highly bound to plasma protein. The concomitant use of TRINTELLIX with another drug that is highly bound to plasma protein may increase free concentrations of TRINTELLIX or other tightly-bound drugs in plasma.

Intervention

Monitor for adverse reactions and reduce dosage of TRINTELLIX or other protein bound drugs as warranted.

Examples

warfarin

The list price for TRINTELLIX is $514.15 for a 30-day prescription.* Eligible commercially insured patients may pay as little as $10 for either a 30-day or 90-day prescription with the TRINTELLIX Savings Card.† Savings of up to $100 per 30-day or $300 per 90-day prescription, with a maximum total savings of up to $1,300 over one year. Restrictions apply.

TRINTELLIX is available for ~85% of commercially insured patients in the US without prior authorization (PA).‡

For more information about savings or for coverage in your area, visit Savings & Support.

*As of 01/01/2025.
†See the Savings Card for Eligibility Requirements and Terms & Conditions.
‡Formulary data are provided by Fingertip Formulary® and are current as of December 2024. Check the patient’s individual health plan for coverage and cost information, which may change without notice.

Contact your local sales rep to request samples; if you don’t have one, you can request a rep here.

If you would like to have TRINTELLIX samples shipped to your office, please visit MySampleCloset and follow the steps below:

  • Login or register to create a new account (upon initial login, you may be prompted to complete a few security questions)
  • View the list of products and select TRINTELLIX
  • Place and submit your order. Maximum order quantities are listed on the site, one order may be placed per month.

Please note that when a TRINTELLIX sample order is placed on the MySampleCloset website, your local Takeda representative will be notified so that they can expedite delivery by bringing them to your office personally. If the representative is unable to deliver your order, the samples will be shipped to your office.

TRINTELLIX is available in 5 mg, 10 mg, and 20 mg tablets.1

For more information, visit our Dosing page, or see Full Prescribing Information.

  • The recommended starting dose is 10 mg administered orally once daily without regard to meals. Dosage should then be increased to 20 mg/day, as tolerated.
    • The efficacy and safety of doses above 20 mg/day have not been evaluated¹
    • A dose decrease down to 5 mg/day may be considered for patients who do not tolerate higher doses
  • Prior to initiating treatment with TRINTELLIX, screen patients for personal or family history of bipolar disorder, mania or hypomania¹
  • The maximum dose is 10 mg/day in patients who are known CYP2D6 poor metabolizers¹
  • Although patients can abruptly discontinue therapy with TRINTELLIX, it is recommended that doses of 15 mg/day or 20 mg/day be reduced to 10 mg/day for 1 week prior to discontinuation¹
    • In placebo-controlled trials, some patients taking more than 10 mg/day experienced transient adverse reactions such as headache and muscle tension following abrupt discontinuation¹
  • Concomitant administration of TRINTELLIX and strong CYP2D6 inhibitors or strong CYP inducers may require a dose adjustment of TRINTELLIX¹

For more information, visit our Dosing page, or see Full Prescribing Information.

For full information on treatment-related side effects and adverse reactions, see Safety Data, Important Safety Information, and the Full Prescribing Information.

What to explore next?

Leaving TRINTELLIXHCP.COM

By clicking “Continue,” you will be leaving a Takeda controlled website for a third-party website.

Please note that Takeda is not responsible or liable for any third-party website, and the website may not be appropriate for all audiences.

CONTINUE
CANCEL

  1. Trintellix (vortioxetine) prescribing information. Takeda Pharmaceuticals.
  2. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. Int J Neuropsychopharmacol. 2012;15(5):589‑600.
  3. Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. J Clin Psychiatry. 2012;73(7):953‑959.
  4. Boulenger J-P, Loft H, Olsen CK. Int Clin Psychopharmacol. 2014;29(3):138‑149.
  5. Mahableshwarkar AR, Jacobsen P, Chen Y, Serenko M, Trivedi MH. Psychopharmacology (Berl). 2015;232(12):2061‑2070.
  6. Jacobsen P, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH. J Clin Psychiatry. 2015;76(5):575‑582.
  7. Katona C, Hansen T, Olsen CK. Int Clin Psychopharmacol. 2012;27(4):215‑223.
  8. Costa SL, Genova HM, DeLuca J, Chiaravalloti ND. Mult Scler. 2017;23(6):772‑789.
  9. McIntyre RS, Lophaven S, Olsen CK. Int J Neuropsychopharmacol. 2014;17(10):1557‑1567.
  10. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RSE. Neuropsychopharmacology. 2015;40(8):2025‑2037.
  11. Data on file. Takeda Pharmaceuticals.
  12. Data on file. Lundbeck.
  13. FDA updates Trintellix® (vortioxetine) label to include data showing improvement in processing speed, an important aspect of cognitive function in acute Major Depressive Disorder (MDD). News release. GlobeNewswire. May 2, 2018.
  14. Boulenger J-P, Loft H, Florea I. J Psychopharmacol. 2012;26(11):1408‑1416.
  15. Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. J Sex Med. 2015;12(10):2036‑2048.
  16. Kambeitz JP, Howes OD. J Affect Disord. 2015;186:358-366.
  17. American Psychiatric Association. Depressive disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 5th edition (DSM-5®). Arlington, VA: American Psychiatric Association; 2013:155‑188.
  18. Conradi HJ, Ormel J, de Jonge P. Psychol Med. 2011;41(6):1165-1174.